Endothelial Protection in Convalescent COVID-19 Patients
Status:
Not yet recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
This pilot open-label randomized controlled trial aims to assess if treatment with sulodexide
may improve the endothelial status and inflammatory response in post-COVID-19 patients.
Survived inpatients with severe-to-critical COVID-19 within 14 days after discharge are
randomized to receive sulodexide 250 LSU 1 oral capsule twice daily or no treatment for 8
weeks. Biomarkers of endothelial dysfunction, inflammation, and prothrombotic changes are
assessed at 0, 4, and 8 weeks. The hypothesis is that affected endothelial function,
pro-inflammatory, and pro-thrombotic changes could be improved with sulodexide treatment in
convalescent COVID-19 patients who suffered a severe-to-critical clinical presentation and
have chronic comorbidities of high risk for endothelial dysfunction.
Phase:
Phase 4
Details
Lead Sponsor:
Pirogov Russian National Research Medical University